Stocksigma LogoStocksigma Logo

Biocon Q2 FY27 Results: Operational Resilience Despite Profitability Pressures

Biocon reported Q2 FY27 revenue from operations of ₹4,389 Cr, up 2% YoY, while EBITDA fell 7% YoY to ₹865 Cr (20% margin)

Biocon Q2 FY27 Results: Operational Resilience Despite Profitability Pressures

Biocon Ltd · Investor Presentation · 04 Nov 2026, 8:40 pm

Biocon Q2 FY27 Results: Operational Resilience Despite Profitability Pressures Biocon reported Q2 FY27 revenue from operations of ₹4,389 Cr, up 2% YoY, while EBITDA fell 7% YoY to ₹865 Cr (20% margin). Net profit before exceptional items declined 52% YoY to ₹44 Cr. Biosimilars revenue rose 3% YoY to ₹2,809 Cr, and Generics grew 10% YoY to ₹774 Cr with margins up over 700 bps. Services revenue dropped 9% YoY to ₹833 Cr but rebounded 13% QoQ. Management anticipates a stronger H2 FY27 driven by biosimilar launches, expanded insulin capacity, and progressive Services recovery.

Original exchange filing (PDF)

More announcements from Biocon Ltd

All Biocon Ltd announcements